Cargando...
Salutary Response to Targeted Therapy in Anaplastic Thyroid Cancer
Context. Anaplastic thyroid cancer (ATC) is an aggressive tumor with a median survival of 3 to 9 months, a 1-year survival of less than 10% and without definitive therapies. Recently, in BRAF V600E mutated ATCs, new targeted therapy using a combination of a BRAF inhibitor, dabrafenib (Dab), with a m...
Gardado en:
| Publicado en: | J Investig Med High Impact Case Rep |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
SAGE Publications
2019
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6880026/ https://ncbi.nlm.nih.gov/pubmed/31766881 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2324709619890942 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|